1/12 The company exhibited at our 2011 conference and has become a corporate conference sponsor for 2012 in San Francisco. (Full disclosure)
5/05 We have now received information from Amarc Enterprises who sell this product. See the section "Some information from Amarc Enterprises" for more.
11/04 The following note was sent by a Long Island-based breast cancer advocate: "Have you heard of the supplement Poly MVA? It drastically helped a woman that I know of get rid of a brain tumor. She had a stage 4 brain tumor with paralysis and after taking Poly MVA her paralysis was gone and an MRI showed that the tumor was gone".
Ann's NOTE: We are hoping the woman referred to above will write up her experiences for us.
Ralph W. Moss, Ph.D. Weekly CancerDecisions.com
Newsletter #105 10/24/03
A FRIENDLY SKEPTIC LOOKS AT POLYMVA, PART TWO
Last week I reported on the emergence of PolyMVA as a
popular "alternative" treatment for cancer. At a
website devoted to the topic (www.polymvasurvivors.com)
there are many anecdotes supposedly proving its
benefits for cancer patients.
In discussing these
cases, I am simply summarizing the anecdotes as given.
I have not independently verified their accuracy.
Patient #1. A 75-year-old female with glioblastoma (an
aggressive form of brain cancer) presented with
history of debulking surgeries and two rounds of
As a last resort her cancer center
neurologist placed her on massive, experimental doses
of tamoxifen. She then entered an unspecified hospital
in Baja California. At the time of admission, she
required support on both arms to walk up the short
ramp, her memory was impaired and her speech was
Convulsions were being kept under control with
dilantin. On the third day after beginning treatment
with PolyMVA, we are told, her memory improved and her
slurred speech became clearer. "She walked out of the
hospital unaided to continue therapy at home," the
website continues, and she lived a further six months.
Her death, we are told, "is attributable to the side
effects of the tamoxifen which she continued to take"
before and after PolyMVA.
This report strikes me as - let me be generous -
uninterpretable. Many patients experience temporary
improvements in well being when they begin new
regimens. The improvement in memory and speech may or
may not have been due to PolyMVA or to anything else
she received at this unspecified Baja California
It is also highly unlikely that this woman's
death could be attributed to the side effects of
tamoxifen. In the long-term, tamoxifen may cause
serious side effects, such as a heightened risk of
endometrial cancer, but there is no indication that
this woman developed that condition, and in the absence
of an autopsy report her death cannot be attributed so
unequivocally to this standard drug.
It is much more
likely that she died of her glioblastoma, despite
taking various drugs, including PolyMVA.
Patient #2. This account is again reproduced from the
www.polymvasurvivors.com website: "Glioblastoma
patients usually have a dramatic, early response
similar to Mr. D. age 66," we are told.
inactivated his right leg and foot and caused
generalized convulsions which were poorly controlled by
tegretol, or dilantin. I received a phone call from Mr.
D. four days after he began LAPd [i.e. PolyMVA]. He
said his paralysis was gone and he could walk outside
and water the lawn and ride his stationary bicycle.
Eight days after beginning he called again to report
that his convulsions were now localized and almost
End of anecdote. Who is the person reporting
this? We aren't told. And what happened to Mr. D? We
don't have any report beyond the first eight days of
Patient #3. "Pain from metastatic breast cancer, to the
spine and right hip in CF age 56 required a right hip
replacement which gave relief from hip pain, but did
not effect [sic] the spine.
She started LAPd and within
2 weeks her 'back pain stopped' and she returned to her
legal research employment. Most breast cancer patients
report at least temporary improvement."
Again, no report beyond a scant two weeks. The woman's
pain may have returned with a vengeance on day 15, for
all we know. No information was supplied on what
ultimately happened to this patient.
Patients #4 and #5. "Two cases of cancer of esophagus:
Both required MS [morphine sulfate, ed.] for pain
relief, both were cachectic [wasting away, ed.].
were terminal when they started LAPd. Mr. G. age 62 was
in a Mexican hospital when he was scheduled to begin
the LAPd. LS age 45 took the LAPd for home use. Mr. G
died within 6 weeks, but an investigation uncovered the
fact hat he was never given the LAPd.
He was given
Laetril [sic] alone. LS reported increased strength and
weight gain and is still living (2 years from starting
Obviously, patient #4 should not be included in any
best case series, since he didn't receive the drug in
question. Patient #5, L.S., is much more interesting,
however. Two years survival with stage IV (cachectic)
esophageal cancer is very unusual.
But we need to know
much more about this case before we can express an
opinion, let alone draw conclusions about the role of
Patient #6. An Alaskan woman who was diagnosed in April
1995 with multiple myleoma. She sent the webmaster a
letter in March 1997 saying that after taking PolyMVA
her blood tests and examinations showed "no measurable
signs of multiple myeloma" and her doctors said she was
in total remission.
In 2002, she reported that she was
beginning her seventh year in remission. "I have no
signs of any cancer and feel very well," she reputedly
wrote. "I am very grateful and hope to carry on this
way for many years to come."
If confirmed, this could be a significant case, since
protracted remissions in multiple myeloma are rare.
However, readers should be aware that there is a form
of the disease called "smoldering myeloma," in which
remissions do occur and survival can be lengthy.
would need to verify the diagnosis and particularly to
rule out the possibility that patient #6 had this form
of the disease before drawing any conclusions about the
contribution of PolyMVA.
There is also a fairly extensive section of
self-described "testimonials" at this site. These are
of variable quality. Patients and their loved ones get
to tell their own stories, which may be salutary for
them. But these anecdotes are sometimes confused and
lacking in relevant details.
Here is one representative
quote from the daughter of a patient: "I lived abroad
for many years in a country awash in superstition. I am
superstitious, in a universal and spiritual sense and
will not venture to put into words, what has
Nor will I make mention of my father's
name. Let it suffice to say that…Poly MVA was God's way
Hard to draw firm conclusions from
What is conspicuously lacking overall is any genuine
scientific support for this treatment. In a recent
email Dr Garnett informed me that he intends to
initiate clinical trials with PolyMVA in India sometime
next year. I look forward to seeing the results when
they are published.
However, there are already over 14
million journal citations, dating back to the 1950s,
listed in PubMed, the National Library of Medicine's
encyclopedic medical database. Over 1.5 million of
these articles are specifically on the topic of cancer.
As a point of reference there are over 4,000 articles
on the mineral palladium in biomedicine.
How many of these articles are on PolyMVA? Zero.
Polydox? Zero. LAPd? Zero. I can find no record of it
at all in the medical literature.
Dr. Garnett has been
researching cancer for 40 years and has focused on
PolyMVA for the last dozen or so. He is the author of
half a dozen or so scientific papers (see references
Yet I could find no scientific articles by Dr.
Garnett or anyone else on the clinical effects of
PolyMVA. The scientific cupboard is bare.
I am familiar with all the obstacles that exist for
publishing innovative medical work. Indeed, a dozen
years ago it was very difficult to get a serious
hearing anywhere for innovative cancer treatments.
today that situation has dramatically changed. The US
government now spends almost $100 million per year
researching alternative medicine. Both the National
Cancer Institute and the National Institutes of Health
have offices whose charge is specifically to examine
There are half a dozen peer-reviewed
journals that are eager to publish findings on
Publication in peer-reviewed journals is the accepted
meeting ground of science: most genuine scientists try
extremely hard to put their research in front of their
The conspicuous absence of peer-reviewed
research on PolyMVA is therefore inexplicable. If there
are really 300 physicians currently using PolyMVA
routinely in cancer treatment, as some of the drug's
proponents suggest, why has none of them published data
on the clinical benefits of the treatment?
How could a
board-certified physician conclude that the "war on
cancer" has been successfully concluded through PolyMVA
and yet not explain the basis of that earthshaking
conclusion in a reputable medical journal?
Even though anecdotal evidence cannot take the place of
thorough clinical trials, such evidence is not entirely
without value as a tentative indicator of merit.
might, for example, be worthwhile for PolyMVA
proponents to carefully sift through the many anecdotes
to put together a serious presentation to the Cancer
Advisory Panel on Complementary and Alternative
Medicine (CAP-CAM) of the National Institutes of
That panel was set up, with great effort,
precisely to review claims of benefit from alternative
treatments. If there were still sufficient interest
after the presentation, this could lay the groundwork
for a proper clinical trial.
Without even the most
basic scientific groundwork, however, the evidence for
PolyMVA's effectiveness remains flimsy at best.
I would also question that easy assumption that PolyMVA
is a "food supplement" and is therefore essentially
non-toxic. I am unaware of any reputable source that
considers palladium a necessary nutrient.
widely used as a component of dental amalgam, and has
therefore come under scrutiny for its toxic potential.
A scientific paper from the Medical College of Georgia
School of Dentistry concluded that "there have been
recent controversies… over possible adverse biological
effects of using palladium in dental alloys."
According to the paper, "in an ionic form and at
sufficiently high concentrations, palladium has toxic
and allergic effects on biological systems…The
carcinogenic potential of the palladium ion is still
unclear, although there is some evidence that it is
capable of acting as a mutagen" (Wataha 1996).
A more recent German review concludes: "A major source
of health concern is the sensitization risk of Pd
[palladium, ed.] as very low doses are sufficient to
cause allergic reactions in susceptible individuals.
Persons with known nickel allergy may be especially
susceptible….Pd salts … may cause primary skin and eye
irritations" (Kielhorn 2002).
Finally, the cost of PolyMVA is considerable: $330 for
an 8 ounce bottle, according to the www.polymva.com
website. This can add up.
The recommended dose for
adult human patients with active cancer is 8 teaspoons
per day. At 6 teaspoons to the fluid ounce, the daily
dose is 1.3 ounces. A bottle will therefore last 6.15
If one took this agent for a year one would need
about 60 bottles, which would cost $19,800. Readers
with cancer would be well advised to save their money
and to look for more credible alternatives.
--Ralph W. Moss, PhD
American Medicine and Research Center web site:
Sinatra S. Here's why some doctors don't get sick. In:
International Council for Health Freedom, Vol. VII, issue
3-4, Winter 2003/Spring 2004.
Garnett M and Krishnan CV. Pulsed electrospinning of
biopolymers. In Press: May 2002.
Garnett M and Remo JL. 200th Meeting of the Electrochemical
Society, No. 1132, September 2001.
Garnett M and Remo JL, DNA reductase: A synthetic enzyme
with opportunistic clinical activity against radiation
sickness., International Symposium on Applications of
Enzymes in Chemical and Biological Defense, Orlando, May
2001, p. 41.
Garnett M and Remo JL. Soluble sensors of telephonic
signals. Microfabricated Systems and Mems V, Proceedings
Vol. 2000-19, The Electrochemical Society, p. 185, October,
Garnett M. Palladium complexes and methods for using same in
the treatment of tumors, U.S. Patent no. 5,679,697, October
Garnett M. Palladium complexes and methods for using same in
the treatment of psoriasis, U.S. Patent no. 5,776,973, July
Garnett M. Thaw indicator device, U.S. Patent no. 4,051,804,
October 4, 1997.
Garnett M. Electrogenetic effect of a synthetic oxygen
carrier. Journal of Cell Biology, v.43,42a, November 1969.
Garnett M. A laboratory model for heterochromatin. Journal
of Cell Biology, v.35,44a, November 1967.
Kielhorn J, Melber C, Keller D, Mangelsdorf I. Palladium--a
review of exposure and effects to human health. Int J Hyg
Environ Health. 2002 Oct;205(6):417-32.
Dr. Taylor's license revocation:
Wataha JC and Hanks CT. Biological effects of palladium and
risk of using palladium in dental casting alloys. J Oral Rehabil.
The news and other items in this newsletter are
intended for informational purposes only. Nothing in
this newsletter is intended to be a substitute for
professional medical advice.
LINK to website w/survivor
LINK to Morton Walker
article from Feb/March 2003
LINK to Dr. Lam article
"An Insider's Guide to Natural Medicine"
Al in Seattle
Report from a Conference that Discussed PolyMVA
Cancer Wire, May 2005
From a June 1006 email
Posted April 16, 2010
|Remember we are NOT Doctors and have NO medical training.|
This site is like an Encyclopedia - there are many pages, many links on many topics.
Support our work with any size DONATION - see left side of any page - for how to donate. You can help raise awareness of CAM.